Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Ischemic Heart Disease

Free Subscription Articles published in J Cardiovasc Pharmacol Retrieve available abstracts of 64 articles: HTML format

Single Articles

October 2025
1. KHATAMI S, Faghihi M, Zarrin A, Sarveazad A, et al
   Cardioprotective Effects of Apelin in Myocardial Ischemia/Reperfusion Injury: A Systematic Review and Meta-Analysis.
   J Cardiovasc Pharmacol. 2025 Oct 28. doi: 10.1097/FJC.0000000000001773.
   PubMed     Abstract available
   
   
   
2. LI J, Li X, Chen Y, Fang L, et al
   Cardioprotective effects of soluble guanylate cyclase and its alpha1 subunit on myocardial ischemia/reperfusion injury via the PGC-1alpha/UCP2 pathway.
   J Cardiovasc Pharmacol. 2025 Oct 13. doi: 10.1097/FJC.0000000000001765.
   PubMed     Abstract available
   
   
   September 2025
3. SALLOUM FN, Raucci FJ
   Remodeling Cardiovascular Research: Ready to Sacrifice Animal Models?
   J Cardiovasc Pharmacol. 2025 Sep 18. doi: 10.1097/FJC.0000000000001759.
   PubMed    
   
   
   August 2025
4. MA M, Xu C, Zhou H, Zhou Y, et al
   Lactylation in Cardiovascular Diseases: Epigenetic Mechanisms and Therapeutic Potential.
   J Cardiovasc Pharmacol. 2025 Aug 15. doi: 10.1097/FJC.0000000000001751.
   PubMed     Abstract available
   
   
   
5. BIONDI-ZOCCAI G, Frati G, Carnevale R, Booz GW, et al
   Human-Based Technologies in Cardiovascular Pharmacology Research.
   J Cardiovasc Pharmacol. 2025 Aug 5. doi: 10.1097/FJC.0000000000001745.
   PubMed     Abstract available
   
   
   July 2025
6. MARCHETTA M, Golino M, Markley JD, Abbate A, et al
   Rare but Severe Cardiovascular Complications of SARS-CoV-2 Vaccination: A Call for Awareness.
   J Cardiovasc Pharmacol. 2025 Jul 24. doi: 10.1097/FJC.0000000000001740.
   PubMed     Abstract available
   
   
   
7. BIONDI-ZOCCAI G, Vassiliou VS, Palumbo MC, Booz GW, et al
   Phthalates and Cardiovascular Risk: A Call for Awareness in Clinical Practice.
   J Cardiovasc Pharmacol. 2025 Jul 18. doi: 10.1097/FJC.0000000000001732.
   PubMed     Abstract available
   
   
   
8. FAGHIHI M, Ahmadi-Beni M, Houshmand F
   Role of Muscarinic Acetylcholine Receptors in Oxytocin-Induced Cardioprotection Against Ischemia-Reperfusion Injury in Rats.
   J Cardiovasc Pharmacol. 2025;86:109-117.
   PubMed     Abstract available
   
   
   May 2025
9. BAHARDOUST M, Yarahmadi D, Aghakhani Z, Mahdi Kakoienejad M, et al
   Comparison of short-term treatment with atorvastatin versus rosuvastatin for preventing contrast-associated acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention: a systematic review and meta-analysis.
   J Cardiovasc Pharmacol. 2025 May 14. doi: 10.1097/FJC.0000000000001718.
   PubMed     Abstract available
   
   
   
10. BURNETT H, Cichewicz A, Natani H, Bhowmik D, et al
    Comparative Efficacy of Non-Statin Lipid-Lowering Therapies in Patients With Hypercholesterolemia at Increased Cardiovascular Risk: An Updated Network Meta-Analysis.
    J Cardiovasc Pharmacol. 2025 May 13. doi: 10.1097/FJC.0000000000001712.
    PubMed     Abstract available
    
    
    April 2025
11. ZHANG C, Du Z, Chen R, Liu X, et al
    Gene- and cell-based therapy in cardiovascular diseases.
    J Cardiovasc Pharmacol. 2025 Apr 30. doi: 10.1097/FJC.0000000000001707.
    PubMed     Abstract available
    
    
    
12. CAPPANNOLI L, Fracassi F, Aurigemma C, Romagnoli E, et al
    COLCHICINE IN ACUTE CORONARY SYNDROMES: A META-ANALYSIS OF 12.602 PATIENTS.
    J Cardiovasc Pharmacol. 2025 Apr 28. doi: 10.1097/FJC.0000000000001706.
    PubMed     Abstract available
    
    
    
13. ABBATE A, Biondi-Zoccai G, Altara R, Booz GW, et al
    Changes for 2025 at Journal of Cardiovascular Pharmacology: Introducing Our Junior Associate Editors, Podcasts, Feature, and New Board Members.
    J Cardiovasc Pharmacol. 2025;85:239-242.
    PubMed    
    
    
    March 2025
14. SADEGHIPOUR P, Talasaz AH, Rashedi S, Jamalkhani S, et al
    A Multifaceted Intervention to Mitigate the Adverse Cardiovascular Effects of Air Pollution: A Feasibility Randomized Controlled Trial.
    J Cardiovasc Pharmacol. 2025 Mar 18. doi: 10.1097/FJC.0000000000001691.
    PubMed     Abstract available
    
    
    February 2025
15. BIONDI-ZOCCAI G, Weber BN, Abbate A, Booz GW, et al
    Cardiac Immunotherapy, Immuno-Cardiology and the Future of Cardiovascular Pharmacology.
    J Cardiovasc Pharmacol. 2025 Feb 27. doi: 10.1097/FJC.0000000000001687.
    PubMed     Abstract available
    
    
    
16. GRAGNANO F, Calabro P, Angiolillo DJ
    Deciphering the Role of In-hospital Bleeding in Acute Coronary Syndromes.
    J Cardiovasc Pharmacol. 2025 Feb 17. doi: 10.1097/FJC.0000000000001685.
    PubMed    
    
    
    
17. PEPE M, Tritto R, Napoli G, Giordano S, et al
    Role of Indobufen in coronary artery disease: the story of a neglected drug. A systematic review.
    J Cardiovasc Pharmacol. 2025 Feb 11. doi: 10.1097/FJC.0000000000001681.
    PubMed     Abstract available
    
    
    
18. SPADAFORA L, Betti M, D'Ascenzo F, De Ferrari G, et al
    Impact of In-Hospital Bleeding on Post-Discharge Therapies and Prognosis in Acute Coronary Syndromes.
    J Cardiovasc Pharmacol. 2025 Feb 10. doi: 10.1097/FJC.0000000000001678.
    PubMed     Abstract available
    
    
    
19. ZHANG K, He C, Tong Y, He Y, et al
    Relationship between ALDH2 Gene Polymorphism and Vasodilative Effect of Nitroglycerin on Coronary Arteries.
    J Cardiovasc Pharmacol. 2025 Feb 10. doi: 10.1097/FJC.0000000000001682.
    PubMed     Abstract available
    
    
    
20. GALATI G, Germanova O
    Mineralocorticoid receptor antagonists in end-stage renal disease under renal replacement therapies: bridging the gap between cardiovascular and systemic benefit, from heart failure to myocardial infarction.
    J Cardiovasc Pharmacol. 2025 Feb 6. doi: 10.1097/FJC.0000000000001677.
    PubMed    
    
    
    
21. ZHAO C, Fu J, Wang Y, Zhou Y, et al
    Latest evidence and perspectives of Panax notoginseng extracts and preparations for the treatment of cardiovascular diseases: a review.
    J Cardiovasc Pharmacol. 2025 Feb 4. doi: 10.1097/FJC.0000000000001670.
    PubMed     Abstract available
    
    
    January 2025
22. BONAVENTURA A, Potere N, Liberale L, Kraler S, et al
    Colchicine in coronary artery disease: Where do we stand?
    J Cardiovasc Pharmacol. 2025 Jan 23. doi: 10.1097/FJC.0000000000001672.
    PubMed    
    
    
    
23. BIONDI-ZOCCAI G, Frati G, Peruzzi M, Bernardi M, et al
    Patient reported outcome measures in cardiovascular research and care: PRO(M)s and CONS.
    J Cardiovasc Pharmacol. 2025 Jan 23. doi: 10.1097/FJC.0000000000001669.
    PubMed     Abstract available
    
    
    
24. ABBATE A, Biondi-Zoccai G, Altara R, Booz GW, et al
    Changes for 2025 at Journal of Cardiovascular Pharmacology: Introducing Our Junior Associate Editors, Podcasts, Feature, and New Board Members.
    J Cardiovasc Pharmacol. 2025 Jan 21. doi: 10.1097/FJC.0000000000001673.
    PubMed    
    
    
    
25. ANTO S, Sun C, O'Rourke ST
    Activation of APJ Receptors by CMF-019, But Not Apelin, Causes Endothelium-Dependent Relaxation of Spontaneously Hypertensive Rat Coronary Arteries.
    J Cardiovasc Pharmacol. 2025 Jan 21. doi: 10.1097/FJC.0000000000001671.
    PubMed     Abstract available
    
    
    
26. SADLER M, Madaudo C, Cannata A, Bromage D, et al
    IL-1 blockade in myocardial infarction and its efficacy in patients with complex coronary artery disease. Another brick in the wall.
    J Cardiovasc Pharmacol. 2025 Jan 2. doi: 10.1097/FJC.0000000000001666.
    PubMed    
    
    
    December 2024
27. JALLORINA A, Vij K, Wan L, Thomas J, et al
    A Decadal Exploration of Cutaneous Adverse Effects of FDA-Approved Cardiovascular Medications: Insights from 2013 to 2023.
    J Cardiovasc Pharmacol. 2024 Dec 5. doi: 10.1097/FJC.0000000000001660.
    PubMed     Abstract available
    
    
    
28. ABBATE A, Van Tassell B, Bogin V, Markley R, et al
    Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment Elevation Myocardial Infarction: Secondary End Points From an International, Double-Blind, Randomized, Placebo-Controlled, Phase 2a Study.
    J Cardiovasc Pharmacol. 2024;84:565-577.
    PubMed     Abstract available
    
    
    November 2024
29. YANJUAN L, Shuangyou D, Ying W, Xing C, et al
    The research progress: Cuproptosis and copper metabolism in regulating cardiovascular diseases.
    J Cardiovasc Pharmacol. 2024 Nov 15. doi: 10.1097/FJC.0000000000001653.
    PubMed     Abstract available
    
    
    
30. DENICOLAI M, Morello M, Golino M, Corna G, et al
    Interleukin-1 Blockade in Patients With ST-Segment Elevation Myocardial Infarction Across the Spectrum of Coronary Artery Disease Complexity.
    J Cardiovasc Pharmacol. 2024 Nov 12. doi: 10.1097/FJC.0000000000001652.
    PubMed     Abstract available
    
    
    
31. GU N, Chen P, Wang X, Shen C, et al
    Association Between the Neutrophil-to-Lymphocyte Ratio and in-Stent Neoatherosclerosis and Plaque Vulnerability: An Optical Coherence Tomography Study.
    J Cardiovasc Pharmacol. 2024;84:506-514.
    PubMed     Abstract available
    
    
    October 2024
32. TIAN RZ, Zhuang DL, Vong CT, He X, et al
    Role of autophagy in myocardial remodeling after myocardial infarction.
    J Cardiovasc Pharmacol. 2024 Oct 25. doi: 10.1097/FJC.0000000000001646.
    PubMed     Abstract available
    
    
    
33. RUBAIY HN
    Canonical Transient Receptor Potential (TRPC) Channels in Cardiovascular Pathology and their Modulators.
    J Cardiovasc Pharmacol. 2024 Oct 15. doi: 10.1097/FJC.0000000000001643.
    PubMed     Abstract available
    
    
    
34. ABBATE A, Van Tassell B, Bogin V, Markley R, et al
    Interleukin-1 blockade with RPH-104 (goflikicept) in patients with ST-segment elevation myocardial infarction (STEMI): secondary endpoints from an international, double blind, randomized, placebo-controlled, phase IIa study.
    J Cardiovasc Pharmacol. 2024 Oct 2. doi: 10.1097/FJC.0000000000001635.
    PubMed     Abstract available
    
    
    September 2024
35. RUSSO F, Palma A, Cacciatore S, Tomarelli E, et al
    Rethinking beta-blockers after ST-elevation myocardial infarction: essential for some, questionable for others.
    J Cardiovasc Pharmacol. 2024 Sep 6. doi: 10.1097/FJC.0000000000001632.
    PubMed    
    
    
    
36. HUANG HM, Ran FY, Chen J, Shen YS, et al
    Outcomes of Ticagrelor Versus High-dose Clopidogrel in CYP2C19 Intermediate Metabolizer Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes.
    J Cardiovasc Pharmacol. 2024;84:347-355.
    PubMed     Abstract available
    
    
    
37. LI YY, Zhong XJ, Luo JT, Zeng CM, et al
    Fondaparinux Sodium for Anticoagulant Therapy After Primary Percutaneous Coronary Intervention: A Single-Center Randomized Trial in China.
    J Cardiovasc Pharmacol. 2024;84:331-339.
    PubMed     Abstract available
    
    
    
38. BABIKER F, Al-Kouh A
    Immunoglobulin-Mediated Cardiac Protection From Ischemia/Reperfusion Injury in Diabetic Rats Is Associated With Endothelial Nitric Oxide Synthase/Glucose Transporter-4 Signaling Pathway.
    J Cardiovasc Pharmacol. 2024;84:319-330.
    PubMed     Abstract available
    
    
    August 2024
39. GIANNINO G, Giacobbe F, Annone U, Ravetti E, et al
    Impact of adherence to beta-blockers in all-comers ST-segment elevation myocardial infarction (STEMI) patients and according to left ventricular ejection fraction (LVEF) at discharge: results from the real-world registry FAST-STEMI.
    J Cardiovasc Pharmacol. 2024 Aug 29. doi: 10.1097/FJC.0000000000001627.
    PubMed     Abstract available
    
    
    
40. SHI J, Guan B, Gong M, He X, et al
    Kirenol alleviates inflammation and oxidative stress to improve myocardial ischemia/reperfusion injury in rats.
    J Cardiovasc Pharmacol. 2024 Aug 22. doi: 10.1097/FJC.0000000000001626.
    PubMed     Abstract available
    
    
    
41. DEL BUONO MG, La Vecchia G, D'Aiello A, Pedicino D, et al
    Clinical Characteristics, Management, and Outcomes in Cardiogenic Shock: Insights From a High-Volume Italian Cardiac Intensive Care Unit.
    J Cardiovasc Pharmacol. 2024;84:210-219.
    PubMed     Abstract available
    
    
    
42. RUSSO V, Fabiani D, Imbalzano E, De Michele M, et al
    Clinical Performance and Persistence on Dual Pathway Inhibition with Rivaroxaban and Aspirin in Real-World Setting.
    J Cardiovasc Pharmacol. 2024;84:170-174.
    PubMed     Abstract available
    
    
    
43. DENG HW, Ye ZM, Hu RT, Qin C, et al
    The Role of Long Noncoding RNAs in Vascular Smooth Muscle Cell Phenotype and the Pathogenesis of Cardiovascular and Cerebrovascular Aneurysms.
    J Cardiovasc Pharmacol. 2024;84:125-135.
    PubMed     Abstract available
    
    
    July 2024
44. DEL BUONO MG, La Vecchia G, Angiolillo DJ
    Antithrombotic treatment regimens in patients undergoing percutaneous coronary revascularization requiring oral anticoagulation: what real-world evidence shows us.
    J Cardiovasc Pharmacol. 2024 Jul 29. doi: 10.1097/FJC.0000000000001619.
    PubMed    
    
    
    
45. WRIGHT CX, Feher A
    From Risk to Resilience: improved outcomes after myocardial infarction in patients with Sjogren's syndrome.
    J Cardiovasc Pharmacol. 2024 Jul 19. doi: 10.1097/FJC.0000000000001615.
    PubMed    
    
    
    
46. ZHANG J, Xiong X, Li J, Luo C, et al
    Valtrate suppresses TNFSF14-mediated arrhythmia after myocardial ischemia-reperfusion via inducing N-linked glycosylation of LTbetaR to regulate MGA/MAX/c-Myc/Cx43.
    J Cardiovasc Pharmacol. 2024 Jul 19. doi: 10.1097/FJC.0000000000001613.
    PubMed     Abstract available
    
    
    
47. SCIAHBASI A, De Rosa S, Gargiulo G, Giacoppo D, et al
    Management of patients treated with oral anticoagulant therapy undergoing percutaneous coronary intervention with stent implantation: the PERSEO Registry.
    J Cardiovasc Pharmacol. 2024 Jul 19. doi: 10.1097/FJC.0000000000001607.
    PubMed     Abstract available
    
    
    
48. LINGYAN Z, Zijia H, Ya Z, Ying Z, et al
    Cardiovascular outcomes of SGLT-2 Inhibitors Across BMI Spectrum in Heart Failure Patients: An Updated Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2024 Jul 8. doi: 10.1097/FJC.0000000000001610.
    PubMed     Abstract available
    
    
    
49. KARAKASIS P, Patoulias D, Giannakoulas G, Fragakis N, et al
    Are We Ready for Expanding the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Myocardial Infarction?
    J Cardiovasc Pharmacol. 2024;84:26-28.
    PubMed    
    
    
    
50. ZHANG X, Sun G, Li Z, Gao W, et al
    Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Acute Myocardial Infarction With or Without Type 2 Diabetes: A Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2024;84:18-25.
    PubMed     Abstract available
    
    
    
51. SIKORSKA M, Chmiel J, Papuga-Szela E, Broniatowska E, et al
    Apixaban Versus Vitamin K Antagonists in Patients With Antiphospholipid Syndrome: A Cohort Study.
    J Cardiovasc Pharmacol. 2024;84:36-44.
    PubMed     Abstract available
    
    
    June 2024
52. HSIAO BY
    Sjogren syndrome and outcomes of acute myocardial infarction: A propensity-score matched analysis of the Nationwide Inpatient Sample 2005-2018.
    J Cardiovasc Pharmacol. 2024 Jun 19. doi: 10.1097/FJC.0000000000001603.
    PubMed     Abstract available
    
    
    
53. BRUOHA S, Galli M, Sabouret P, Yosefy C, et al
    Atherosclerotic Plaque Erosion: Mechanisms, Clinical Implications, and Potential Therapeutic Strategies-A Review.
    J Cardiovasc Pharmacol. 2024;83:547-556.
    PubMed     Abstract available
    
    
    
54. ZHANG W, Zhang W, Gu N, Qiu Z, et al
    Naturally Occurring Atherosclerosis Progression and In-stent Restenosis: Exploring Histomorphologic Associations Using Optical Coherence Tomography.
    J Cardiovasc Pharmacol. 2024;83:646-654.
    PubMed     Abstract available
    
    
    May 2024
55. ROMEO FJ
    Dual Pathway Inhibition in Stable Cardiovascular Disease: It Takes Two to Tango!
    J Cardiovasc Pharmacol. 2024 May 31. doi: 10.1097/FJC.0000000000001599.
    PubMed    
    
    
    
56. HU D, Qin D, Kuang J, Yang Y, et al
    Metformin-induced PCSK9 inhibition further decreases LDL-C following statin treatment in patients with coronary artery disease and without diabetes.
    J Cardiovasc Pharmacol. 2024 May 21. doi: 10.1097/FJC.0000000000001592.
    PubMed     Abstract available
    
    
    
57. LUZ DE CASTRO A, Ortiz VD, Hickmann AR, Lacerda DS, et al
    EFFECTS OF PTEROSTILBENE ON HEART AND LUNG OXIDATIVE STRESS PARAMETERS IN TWO EXPERIMENTAL MODELS OF CARDIOVASCULAR DISEASE: MYOCARDIAL INFARCTION AND PULMONARY ARTERIAL HYPERTENSION.
    J Cardiovasc Pharmacol. 2024 May 4. doi: 10.1097/FJC.0000000000001572.
    PubMed     Abstract available
    
    
    
58. ZANG G, Chen Y, Guo G, Wan A, et al
    Protective Effect of CD137 Deficiency Against Postinfarction Cardiac Fibrosis and Adverse Cardiac Remodeling by ERK1/2 Signaling Pathways.
    J Cardiovasc Pharmacol. 2024;83:446-456.
    PubMed     Abstract available
    
    
    April 2024
59. LU B, Feng Z, Wang Y, Liao J, et al
    N-n-butyl haloperidol iodide mitigates myocardial ischemia/reperfusion injury through activation of SIRT1-Nrf2 signaling loop.
    J Cardiovasc Pharmacol. 2024 Apr 2. doi: 10.1097/FJC.0000000000001550.
    PubMed     Abstract available
    
    
    
60. ZHANG M, Peng W, Yin S, Zhao Y, et al
    Nondual Antiplatelet Therapy Versus Dual Antiplatelet Therapy Before Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2024;83:297-305.
    PubMed     Abstract available
    
    
    March 2024
61. SIMEONE B, Rocco E, Biondi-Zoccai G, Versaci F, et al
    N-Acetylcysteine: The Next Best Thing for Cardiovascular Interventions and Surgery?
    J Cardiovasc Pharmacol. 2024 Mar 14. doi: 10.1097/FJC.0000000000001558.
    PubMed    
    
    
    
62. GAO L, Wang Q, Li MY, Zhang MM, et al
    A mechanism for the treatment of cardiovascular and renal disease.
    J Cardiovasc Pharmacol. 2024 Mar 14. doi: 10.1097/FJC.0000000000001562.
    PubMed     Abstract available
    
    
    
63. MARTINEZ NAYA N, Toldo S, Abbate A
    Colchicine Leads the Charge in Post-percutaneous Coronary Intervention Anti-inflammatory Defense.
    J Cardiovasc Pharmacol. 2024;83:231-233.
    PubMed    
    
    
    February 2024
64. RT W
    Oral Oncolytics and Cardiovascular Risk Management and Monitoring: Erratum.
    J Cardiovasc Pharmacol. 2024 Feb 15. doi: 10.1097/FJC.0000000000001500.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge.